Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Itway turns to 1H 2026 net loss of EUR 509,000; revenue falls 21% to EUR 28.6 million

Itway turns to 1H 2026 net loss of EUR 509,000; revenue falls 21% to EUR 28.6 million

BitgetBitget2026/09/30 15:41
  • Itway first-half 2026 revenue fell 21% to EUR 28.6 million, while net result swung to a loss of EUR 509,000.
  • EBITDA dropped 79% to EUR 259,000, and EBIT turned to a loss of EUR 297,000.
  • Management said the first half was affected by a shift of EUR 7.5 million of key orders at its Turkish unit into 2H 2026.
  • Net financial position improved to EUR -4.37 million from EUR -4.64 million at Dec. 31, 2025.
  • Orders rose 18.5% in the Data Science business unit, while Cybersecurity and Cybersafety operating revenue increased 5%.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Itway S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 0524-30-2026_TELEBORSA.pdf), on September 30, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Why did the Reserve Bank of Australia raise interest rates two weeks ago? Meeting minutes reveal inflation risks have become a reality, and waiting would be too costly

The Reserve Bank of Australia acknowledges that the trade-off between inflation and full employment has worsened, but maintains that its goal is to return the Consumer Price Index (CPI) to the 2-3% target range.

智通财经•2026/10/13 02:41

Three-year remission rate up to 94%! Johnson & Johnson (JNJ.US) Tremfya Crohn's disease study shows positive long-term results

Long-term data from two Phase 3 clinical trials by Johnson & Johnson show that adult Crohn's disease patients treated with Tremfya (guselkumab) achieved a clinical remission rate of up to 94% over three years.

智通财经•2026/10/13 01:56